ACAD · Acadia Pharmaceuticals Inc
$29.24
+0.20 (+0.67%)
At close · Aug 21
Market Cap
$5.00B
Shares
172.31M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$29.04
Open$30.00
Day$28.95–30.00
52W close$20.06–30.21
Avg vol 30d1.7M
Short int10.8M · 6.3% float · 8.0d
Short vol59%
Last earningsAug 4, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 5
Up next
Next earnings call
Nov 3, 2026
Est · unconfirmed
· in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 5, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Strong Buy
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Excellent
Quant / Vol
Moderate
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+20%
above
Price vs 50-day avg
+13%
above
RSI (14)
60
neutral
MACD trend
Positive
52-week position
88%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+17%
trailing
6-month return
+18%
trailing
YTD return
+9%
this year
Relative strength
+7%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $26 › 200d $24 — 50d above 200d
Institutional flow
Accumulating
+1% holders QoQ · +49 funds added
Insider flow
Distributing
Net -$547.1K over 90 days · 100% sells
Short interest
Falling
6.27% of float · ▼ -2.0% MoM · 8.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
351 holders — near 3-yr high, broad support
Squeeze score
75
high risk · 0–100
Fundamentals
Revenue growth
+40%
Y/Y
Gross margin
94%
contracting
EPS growth
+69%
Y/Y
Free cash flow
$105.1M
Valuation
P/E 13
below peers
Balance sheet
$177.7M
net cash
Quant / Vol
risk profile
Volatility
38%
annualized · 1-yr
Max drawdown
−28%
past year
ATR
3.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 4, 2026
Total revenues
· Full Year 2026
GAAP
Initiated
$1.24B – $1.3B
prior FY $1.07B
midpoint +18.5% Y/Y
NUPLAZID net product sales
· Full Year 2026
GAAP
Initiated
$760M – $790M
DAYBUE (including all forms of trofinetide) global net product s
· Full Year 2026
GAAP
Initiated
$480M – $510M
R&D expense
· Full Year 2026
GAAP
Initiated
$355M – $380M
SG&A expense
· Full Year 2026
GAAP
Initiated
$660M – $700M
Prior guidance
period ended
· from the 8-K filed Jan 13, 2026
Net sales
· 2025
at least $1B
Guided vs delivered
· last 1 settled
Total Revenues (U.S. only)
Full Year 2025
guided $1.05B – $1.1B
$1.07B
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+20%
Bullish
Price vs 50-day avg
+13%
Bullish
RSI (14)
60
Neutral
MACD trend
Positive
Bullish
52-week position
88%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $26 › 200d $24 — 50d above 200d
Institutional flow
Accumulating
+1% holders QoQ · +49 funds added
Insider flow
Distributing
Net -$547.1K over 90 days · 100% sells
Short interest
Falling
6.27% of float · ▼ -2.0% MoM · 8.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
351 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $20
Now $29 · 88%
Range high $30
vs 200-day avg +20%
vs 50-day avg +13%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| DAYBUE products Net Sales | $124.8M | 2Q26 | +29.9% |
|
|
|||
| Non-GAAP Adjusted NUPLAZID Net Sales non-GAAP | $183.2M | 2Q26 | — |
|
|
|||
| Non-GAAP Adjusted Total Revenues non-GAAP | $308M | 2Q26 | — |
|
|
|||
| DAYBUE Net Sales | $101.2M | 1Q26 | — |
| NUPLAZID volume growth | 9% | FY25 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ACAD
this stock
Acadia Pharmaceuticals Inc
|
$5.00B | +8.7% | +40.4% | 13.0 | 6.3% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +21.5% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
MRNA
Moderna, Inc.
|
$69.62B | +352.1% | +4.3% | — | 12.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ACAD | +2.3% | +17.0% | +18.2% | +12.3% | +8.7% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +4.3% | +13.7% | +7.1% | +10.2% | -3.1% |
Key facts
CIK
1070494
CUSIP
004225108
13F (30d)
343 filings
313 filers
Visit website
Investor relations